GLMD - Galmed Pharmaceuticals Ltd.
| Previous Close | 8.21 |
| Open | 8.18 |
| Bid | 8.26 x 1000 |
| Ask | 9.00 x 1100 |
| Day's Range | 8.16 - 8.37 |
| 52 Week Range | 5.36 - 27.06 |
| Volume | 46,121 |
| Avg. Volume | 119,964 |
| Market Cap | 174.605M |
| Beta (3Y Monthly) | 2.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.54 |
| Earnings Date | May 7, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.00 |
- PR Newswire•16 days ago
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
TEL AVIV, Israel, April 9, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis, announced today that the company has completed its End-of-Phase 2 meeting with the Food and Drug Administration (FDA) and reached general agreement on key aspects of the Phase 3/4 development and registration plan for Aramchol and on the pivotal registration study ARMOR. ARMOR is a Phase 3/4 multinational, multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of Aramchol in subjects with NASH and fibrosis.
- Zacks•last month
Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire•last month
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , March 13, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- Simply Wall St.•last month
Update: Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Gained 95% In The Last Three Years
It hasn't been the best quarter for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shareholders, since the share price has fallen 17% in that time. But that doesn't change the fact that theRead More...
- PR Newswire•last month
Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
The aim of this Phase I, open-label, two-period, randomized, crossover PK study was to assess whether dose splitting of Aramchol 600mg to twice daily 300mg will significantly increase plasma levels. 16 healthy subjects took part in two study periods.
- PR Newswire•2 months ago
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
TEL AVIV, Israel , March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- Zacks•4 months ago
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
- Simply Wall St.•4 months ago
What does Galmed Pharmaceuticals Ltd.’s (NASDAQ:GLMD) Balance Sheet Tell Us About Its Future?
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
- Zacks•4 months ago
Novan Announces Top-Line Data From Mid-Stage Molluscum Study
Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.
- Zacks•5 months ago
Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher
Galmed Pharmaceuticals (GLMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- GlobeNewswire•5 months ago
Recent Analysis Shows COUPA SOFTWARE, Galmed Pharmaceuticals, Sunworks, Murphy, Diversicare Healthcare Services, and Pro-Dex Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•5 months ago
Phase 2 Data for Galmed Pharmaceutical's Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018
TEL AVIV, Israel, Nov. 13, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today the oral abstract presentation of one-year results of the Company's global Phase 2b ARREST study of Aramchol in patients with non-alcoholic steatohepatitis (NASH).
- Zacks•5 months ago
Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Galmed Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•6 months ago
Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 64.29% and 400.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 months ago
Galmed Pharmaceuticals: 3Q Earnings Snapshot
The Tel Aviv, Israel-based company said it had a loss of 5 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
- PR Newswire•6 months ago
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- Insider Monkey•6 months ago
Nantahala Capital Management’s Returns, AUM, and Holdings
Nantahala Capital Management is a New Haven-based hedge fund founded in 2004 by 26-year-old Wilmot Harkey. He named his firm after the river in the Smoky Mountains which he visited with his family when he was a kid, as he wanted a name that would remind him of his background. Although, Wil Harkey was very young […]
- PR Newswire•6 months ago
Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
TEL AVIV, Israel , Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- Simply Wall St.•6 months ago
Who Really Owns Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)?
A look at the shareholders of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...
- PR Newswire•7 months ago
Galmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol™ to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting®
TEL AVIV, Israel , Oct. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- PR Newswire•7 months ago
Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference
TEL AVIV, Israel , Sept. 27, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator ...
- Zacks•9 months ago
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
- Zacks•9 months ago
Galmed Pharmaceuticals (GLMD) Reports Q2 Loss
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -6.25% and 0.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•9 months ago
Galmed Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 17 cents. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
- PR Newswire•9 months ago
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Aug. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
